Printer Friendly

Relapsed Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H1, 2014.

NEW YORK, June 17, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Relapsed Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H1, 2014 http://www.reportlinker.com/p02154179/Relapsed-Chronic-Lymphocytic-Leukemia-CLL-Global-Clinical-Trials-Review-H1-2014.html

Relapsed Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, "Relapsed Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H1, 2014" provides data on the Relapsed Chronic Lymphocytic Leukemia (CLL) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Relapsed Chronic Lymphocytic Leukemia (CLL). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Relapsed Chronic Lymphocytic Leukemia (CLL). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Table of Contents Introduction 7 Relapsed Chronic Lymphocytic Leukemia (CLL) 7 Report Guidance 7 Clinical Trials by Region 8 Clinical Trials and Average Enrollment by Country 9 Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11 Top Five Countries Contributing to Clinical Trials in Europe 12 Top Countries Contributing to Clinical Trials in North America 13

Top Countries Contributing to Clinical Trials in Middle East and Africa 14 Top Countries Contributing to Clinical Trials in Central and South America 15 Clinical Trials by G7 Countries: Proportion of Relapsed Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials 16 Clinical Trials by Phase in G7 Countries 17 Clinical Trials in G7 Countries by Trial Status 18 Clinical Trials by E7 Countries: Proportion of Relapsed Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials 19 Clinical Trials by Phase in E7 Countries 20 Clinical Trials by Phase 21 In Progress Trials by Phase 22 Clinical Trials by Trial Status 23 Clinical Trials by End Point Status 24 Unaccomplished Trials of Relapsed Chronic Lymphocytic Leukemia (CLL) 25 Subjects Recruited Over a Period of Time 26

Clinical Trials by Sponsor Type 27 Prominent Sponsors 28 Top Companies Participating in Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials 29 Prominent Drugs 30 Latest Clinical Trials News on Relapsed Chronic Lymphocytic Leukemia (CLL) 31 Dec 09, 2013: Emergent BioSolutions Presents Positive Interim Phase 2 Data Evaluating Otlertuzumab in Combination with Bendamustine in People with Relapsed Chronic Lymphocytic Leukemia 31 Dec 09, 2013: Interim Phase IIa Results for Spiegelmer Olaptesed Pegol in CLL and MM Studies 31 Nov 25, 2013: TG Therapeutics Initiates First Combination Clinical Trial of TG-1101 and TGR-1202 in Patients With Relapsed and/or Refractory CLL and NHL 33 Oct 07, 2013: MorphoSys and Xencor Provide Update on Phase 1/2a Trial in CLL/SLL for MOR208 33 Clinical Trial Profiles 35 Clinical Trial Overview of Top Companies 35 F. Hoffmann-La Roche Ltd. 35 Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 35 Pharmacyclics, Inc. 37

Clinical Trial Overview of Pharmacyclics, Inc. 37 GlaxoSmithKline plc 38 Clinical Trial Overview of GlaxoSmithKline plc 38 Celgene Corporation 39 Clinical Trial Overview of Celgene Corporation 39 AbbVie Inc. 40 Clinical Trial Overview of AbbVie Inc. 40 Janssen Global Services, LLC 41 Clinical Trial Overview of Janssen Global Services, LLC 41 Sanofi 42 Clinical Trial Overview of Sanofi 42 Gilead Sciences, Inc. 43 Clinical Trial Overview of Gilead Sciences, Inc. 43 Bristol-Myers Squibb Company 44 Clinical Trial Overview of Bristol-Myers Squibb Company 44 AstraZeneca PLC 45 Clinical Trial Overview of AstraZeneca PLC 45 Clinical Trial Overview of Top Institutes / Government 46 National Cancer Institute 46 Clinical Trial Overview of National Cancer Institute 46

The University of Texas M. D. Anderson Cancer Center 47 Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center 47 Ohio State University Comprehensive Cancer Center 48 Clinical Trial Overview of Ohio State University Comprehensive Cancer Center 48 Massachusetts General Hospital 49 Clinical Trial Overview of Massachusetts General Hospital 49 Eastern Cooperative Oncology Group 50 Clinical Trial Overview of Eastern Cooperative Oncology Group 50 Fred Hutchinson Cancer Research Center 51 Clinical Trial Overview of Fred Hutchinson Cancer Research Center 51 Roswell Park Cancer Institute 52 Clinical Trial Overview of Roswell Park Cancer Institute 52 University of Kentucky 53 Clinical Trial Overview of University of Kentucky 53 Beth Israel Deaconess Medical Center 54 Clinical Trial Overview of Beth Israel Deaconess Medical Center 54 Duke University 55 Clinical Trial Overview of Duke University 55 Five Key Clinical Profiles 56 Appendix 182 Abbreviations 182 Definitions 182 Research Methodology 183 Secondary Research 183 About GlobalData 184 Contact Us 184 Disclaimer 184 Source 185

List of Tables Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Region, 2014* 8 Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 9 Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 10 Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 11 Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 12 Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, North America, Top Countries, 2014* 13 Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 14 Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 15 Proportion of Relapsed Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials, G7 Countries (%), 2014* 16

Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 17 Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 18 Proportion of Relapsed Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials, E7 Countries (%), 2014* 19 Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 20 Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Phase, 2014* 21 Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22 Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23 Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24

Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Terminated Clinical Trials, 2014* 25 Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26 Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 27 Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28 Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 29 Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 30 Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014* 35 Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Pharmacyclics, Inc., 2014* 37 Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014* 38 Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Celgene Corporation, 2014* 39 Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by AbbVie Inc., 2014* 40 Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Janssen Global Services, LLC, 2014* 41 Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014* 42

Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Gilead Sciences, Inc., 2014* 43 Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Bristol-Myers Squibb Company, 2014* 44 Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014* 45 Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014* 46 Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2014* 47 Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Ohio State University Comprehensive Cancer Center, 2014* 48

Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Massachusetts General Hospital, 2014* 49 Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Eastern Cooperative Oncology Group, 2014* 50 Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Fred Hutchinson Cancer Research Center, 2014* 51 Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Roswell Park Cancer Institute, 2014* 52 Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Kentucky, 2014* 53 Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Beth Israel Deaconess Medical Center, 2014* 54 Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Duke University, 2014* 55

List of Figures Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Region (%), 2014* 8 Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 9 Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 10 Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 11 Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 12 Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 13 Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014* 14 Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2014* 15 Proportion of Relapsed Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials, G7 Countries (%), 2014* 16 Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 17

Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 18 Proportion of Relapsed Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials, E7 Countries (%), 2014* 19 Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 20 Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21 Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22 Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23 Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24 Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26 Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 27 Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28 Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 29 Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 30 GlobalData Methodology 183

To order this report: Relapsed Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H1, 2014 http://www.reportlinker.com/p02154179/Relapsed-Chronic-Lymphocytic-Leukemia-CLL-Global-Clinical-Trials-Review-H1-2014.html

_________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

SOURCE Reportlinker
COPYRIGHT 2014 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 17, 2014
Words:2152
Previous Article:Global Mobile M2M Module Market 2014-2018.
Next Article:Amnesia Global Clinical Trials Review, H1, 2014.
Topics:

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters